Daniela Dinulescu

Company: AstraZeneca

Job title: Director

Seminars:

Combination Strategies to Maximize the Benefit of IO Therapies 12:30 pm

• Understanding the synergistic potential of combination therapies in enhancing the effectiveness of immunotherapies • Exploring the rational design and selection of complementary agents for optimal combination strategies in the context of immuno-oncology • Examining preclinical tumor models as valuable tools to evaluate and predict the efficacy of combination therapies in guiding clinical decision-makingRead more

day: Day One Track B AM

Fireside Chat: The Future of Preclinical Tumor Models 2:45 pm

• How can we use preclinical models to streamline drug development and make it more cost-effective? • Highlighting the importance of optimizing translatability into the clinic – the next steps • How can models be used in the context of precision oncology? Moderated by: Katie Grausam, Postdoctural Scientist, Cedards-Sinai Medical CenterRead more

day: Day Two

Panel Discussion: Selecting The Best Model Depending on the Cancer Type: How To Do This? 8:30 am

• Pros and cons of the most commonly implemented models • Strategies to select the most appropriate model for your cancer study • Context of use for drug combination studies Moderated by: Daniela Dinulescu, Director, Tumor Immunobiology, ICC Discovery Group, Oncology R&D, Astra ZenecaRead more

day: Day One